Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records

By sjmartinez • August 4, 2023

Beaufils M, Amodru V, Tejeda M, Boher JM, Zemmour C, Chanez B, Chrétien AS, Gorvel L, Gravis G, Bruyat D, Mari R, Madroszyk A, Cuny T, Gonçalves A, Lisberg AE, Olive D, Tassy L, Castinetti F, Rochigneux P. Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records. J Immunother Cancer. 2023 Aug;11(8):e006786. doi: 10.1136/jitc-2023-006786. PMID: 37536938.

Tags: Hematology/Oncology, immune checkpoint inhibitors, immunotherapy, Publications

Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers

Shachar EK, Silverstein J, Gornbein J, Salani R, Karlan BY, Chase DM. Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related[...]

Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE

Rugo HS, Tolaney SM, Chan N, Borges G, Yerushalmi R, Sharifi MN, McHayleh W, Beck T, Vidula N, Hamilton E, Rinn KJ, O'Shaughnessy J, Curigliano[...]

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N,[...]